Health News Releases

  • Today April 10
March 08, 2016 18:00
New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma - Regardless of Allergy Subtype[1,2,3]
Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance therapies helps improve lung functi
March 08, 2016 14:35
Seegene Technologies to Unleash Customized Multiplex PCR Solutions and Support for U.S. Market
Seegene Technologies, Inc., a wholly-owned subsidiary of Seegene, Inc. (096530. KQ) (http://goo.gl/SCVQW1), a global developer of multiplex molecular technologies and multiplex clinical molecular diag
March 08, 2016 12:15
Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress
Celgene Corporation (NASDAQ: CELG) today announced that long-term safety findings from ongoing clinical trials of OTEZLA® (apremilast), the Company‘s oral, selective inhibitor of phosphodiesterase 4 (
March 08, 2016 12:10
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
AbbVie (NYSE:ABBV) and Boehringer Ingelheim today announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psorias
March 08, 2016 12:00
Quintiles Named as a 2016 World’s Most Ethical Company by the Ethisphere Institute
Quintiles, the world’s largest provider of product development and integrated healthcare services, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standa
March 07, 2016 11:15
Quintiles and the American College of Surgeons Announce Agreement to Develop Clinical Registry of the Future
Quintiles and the American College of Surgeons (ACS) today announced a six-year strategic services agreement to improve data collection and quality reporting for all ACS clinical registries. Working t
March 07, 2016 10:05
Oral OTEZLA® (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE™ Trials to Be Presented at American Academy of Dermatology Congress
Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients
March 04, 2016 10:30
GORE® EXCLUDER® Iliac Branch Endoprosthesis Gains FDA Approval
At the Houston Aortic Symposium today, W. L. Gore & Associates, Inc. (Gore) announced the Food and Drug Administration (FDA) approval of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE), making i
March 02, 2016 19:55
ReSound® Introduces the World’s Smartest Super Power Hearing Aid
Today, GN ReSound announced the global launch of ReSound ENZO2™, bringing the renowned benefits of ReSound LiNX2™ to people with severe to profound hearing loss in need of a Super Power solution. A
March 02, 2016 11:45
Alexion Employees Across the Globe Join Together to Support Rare Disease Day 2016
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) joins the worldwide rare disease community in honoring the ninth annual international Rare Disease Day. Rare Disease Day takes place the last day of Februar
March 02, 2016 09:40
European Committee for Medicinal Products for Human Use recommends approval of Giotrif® (afatinib) for advanced squamous cell cancer of the lung
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) (http://goo.gl/fbcEKu) issued a positive opinion (http://goo.
February 29, 2016 17:40
New survey gives voice to people living with a rare and devastating lung disease: “When I think of IPF I think of breathlessness”
An international survey of over 500 people living with idiopathic pulmonary fibrosis (IPF) in more than 20 countries worldwide reveals the real-life emotions faced by those with the devastating diseas
February 29, 2016 11:30
Mitsubishi Tanabe Pharma Corporation Signs Licensing Agreement with A. Menarini Asia-Pacific for Spedra (Avanafil) in 10 Countries in Asia-Pacific
Mitsubishi Tanabe Pharma Corporation (TSE: 4508), and Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini AP”) have entered into a licensing agreement to commercialize and promote SPE
February 26, 2016 17:40
Manipal Hospitals is the First in India to Adopt Masimo Patient SafetyNet™
Masimo (NASDAQ: MASI) announced today that Manipal Hospitals is the first hospital in India to install Masimo Patient SafetyNet™, a remote monitoring and clinician notification system. “With Patien
February 26, 2016 14:30
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
Pooled analysis from the TOMORROW and INPULSIS® trials, recently published in Respiratory Medicine, provides further evidence that OFEV® (nintedanib) significantly reduces the risk of acute exacerbati
February 24, 2016 16:20
Primex Pharmaceuticals: New Acquisition Brings an Innovative Oral Solution for Pediatric Anesthesiology to the Market
Swiss pharmaceutical company Primex Pharmaceuticals AG and French pharmaceutical laboratory Advicenne SA announced today a deal where Primex will acquire global rights for an advanced oral pharmaceuti
February 23, 2016 21:55
Quintiles Named to Fortune Magazine's 2016 List of “World’s Most Admired Companies”
Quintiles, the world’s largest biopharmaceutical services company, has been named to Fortune magazine’s “World’s Most Admired Companies” list for 2016, the second year in a row for this distinction.
February 23, 2016 01:00
InFo Instant Focus© - A Revolution in Natural Lens Surgery for Cataract
The company Swiss Advanced Vision (SAV-IOL SA - www.sav-iol.com) announced the launch of a product without competition in the medical field. The intraocular lens (IOL) InFo Instant Focus© indicated fo
February 19, 2016 14:10
Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS
Celgene Corporation (NASDAQ:CELG) today announced 72-week results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulator, in patients with relapsing m
February 18, 2016 13:55
SAB Biotherapeutics Produces New Human Antibody Treatment for MERS-CoV
SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today it has produced a new human antibody therapeutic to treat the deadly Middle East respiratory syndrome
February 18, 2016 12:00
Australian Expert in Sports Science and Nutrition Joins Herbalife Nutrition Advisory Board
Global nutrition company, Herbalife announced today that Dr. Darren Burgess, an expert in sports science and nutrition, has become the first Australian appointed to its Nutrition Advisory Board (NAB).
February 17, 2016 11:50
GORE® EXCLUDER® Device Reaches Significant Milestone
W. L. Gore & Associates, Inc. (Gore) (www.goremedical.com) today announced that more than 250,000 patients have been treated* with the GORE® EXCLUDER® AAA Endoprosthesis. The GORE EXCLUDER Device has
February 16, 2016 22:00
Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016
Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present
February 15, 2016 11:15
CiteAb Names Cell Signaling Technology, “Antibody Company of the Year” and “Researchers’ Choice”
Cell Signaling Technology (CST), a leading provider of antibodies, kits and services, was honored with the 2016 CiteAb Award for “Researchers’ Choice” and for a second year in a row with the award for
February 12, 2016 13:05
Morinaga Milk's B. longum BB536 Probiotic May Prevent Intestinal Disorders Induced by Animal-Based Diet
Morinaga Milk Industry Co., Ltd. (www.morinagamilk.co.jp/english) (TOKYO:2264), a leading dairy product company in Japan, today unveiled new research showing that daily consumption of yogurt fortified
25 per page50 per page75 per page100 per page